NGeneBio Reports Q2 Sales of 12.45 Billion Won, Up 574% Year-on-Year
Operating Loss Improves by 55.8%
NGS Precision Diagnostics Sales Up 80.7%
Overseas Diagnostic Sales Rise 102%
Blood Cancer Panel Sales Surge 114%
NGeneBio announced on August 14 that it recorded sales of 12,452,070,000 won and an operating loss of 1,185,370,000 won in the second quarter of this year. Sales increased by 574% compared to the same period last year, while the operating loss improved by 55.8%.
Sales from the company's core business, the NGS (Next-Generation Sequencing) precision diagnostics division, amounted to 1,351,440,000 won, marking an 80.7% increase year-on-year. Domestic sales grew by 77.2%, while overseas sales rose by 102.1%.
Overseas, sales of blood cancer diagnostic panels surged 114% compared to the same quarter last year. The share of new markets such as Southwest Asia and the Middle East expanded from 6.1% in the second quarter last year to 34.6% this year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
NGeneBio plans to expand its 'NGS Total Solution' business—which combines NGS equipment, diagnostic panels, and analysis software—in the second half of the year, and to commercialize its AI pathology analysis software, NPAS. Internationally, it aims to expand supply in existing Southeast Asian and European markets, while also strengthening its market entry strategy for new regions such as Southwest Asia and the Middle East.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.